Loading
PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Doxorubicin. Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes clinical 0.67, affected pathway 0.86, literature 0.99, genetic association 0.31, somatic mutation 0.86, animal model 0.39). IntOGen calls it a driver in 5 cohorts (4 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Glioblastoma Multiforme, Prostate Adenocarcinoma.
In plain words · PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
PIK3CB is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.
No product in this corpus aims at PIK3CB yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PIK3CB: RNA low tissue specificity; no normal tissue stained high; highest cancer staining carcinoid (2 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Sarcomas (soft tissue, bone, GIST), Prostate cancer, Bladder & urothelial cancer, Skin cancer (all types), Lung cancer (all types), Ovarian cancer and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P42338; CIViC gene PIK3CB; IntOGen PIK3CB; Human Protein Atlas PIK3CB tissue; Open Targets ENSG00000051382 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Hu et al, Mol. Cell. Biol, 1993, "Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85". Source.
Sources: HGNC HGNC:8976 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42338 (protein name, function text, keywords and locations (REST API)); CIViC gene PIK3CB (2 evidence items, 0 assertions, 2 variants; diseases: Sarcoma (GraphQL API, CC0)); Open Targets ENSG00000051382 (association with cancer (MONDO_0004992) 0.82; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, ovarian cancer 0.51, head and neck squamous cell carcinoma 0.50, skin cancer 0.55, breast cancer 0.67, lung cancer 0.54 (GraphQL API, CC0)); IntOGen PIK3CB (driver in 5 cohorts (Act 4, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signalling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G protein-coupled receptor (GPCR) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signalling pathways for stable platelet adhesion and aggregation. Location: Cytoplasm; Nucleus (UniProt). Locus 3q22.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high; medium in Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Caudate and more.
Medium only: glioma, head and neck cancer, lung cancer, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PIK3CB" OR ABSTRACT:"PIK3CB" OR TITLE:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" OR ABSTRACT:"phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta" OR TITLE:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform" OR ABSTRACT:"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform" OR TITLE:"PIK3C1" OR ABSTRACT:"PIK3C1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PIK3CB, not a curated reading list.